“I think AI technology will become a trend that is a must, not an option, in the pharma market, where unmet needs continuously emerge,” predicts HeaKyoung Cho, chief strategy officer and president of Syntekabio Inc., a South Korean artificial intelligence drug discovery company.
The Korean market for AI-driven drug development remains small and still at an early stage compared to major markets such...